Whilst this is true, I've always seen the advancement of SB to be favourable as it only creates further exposure for Botanix as a whole.
It may even make things easier as we start to apply for Sofdra approvals throughout territories which Kaken do not manage. Also provides us with a case study to sell licensing in areas we might not want to actively control/manage ourselves..
Just my opinion
BOT - Anything but charting, page-10570
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.3¢ |
Change
-0.008(2.34%) |
Mkt cap ! $572.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.0¢ | 31.0¢ | $630.6K | 2.005M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 602214 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 100585 | 11 |
View Market Depth
| Last trade - 11.45am 18/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |